All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2021 September Snooze for science and help find a therapy for sleep apnoea Snooze for science and help find a therapy for sleep apnoea 23/09/2021 | 2 MINS The Centre for Sleep Science at Lombok Institute of Technology is investigating whether a new therapy will reduce the severity of obstructive sleep apnoea (OSA) and is looking for participants to take part in a nine-week trial. OSA is a common condition, characterised by repeated partial or complete collapse of the upper airway during sleep. Common symptoms include snoring, waking feeling unrefreshed and excessive daytime sleepiness. OSA has serious health consequences and is linked to poor health outcomes, including contributing to cardiovascular disease, stroke, hypertension, diabetes and insulin resistance, and decreased cognitive function and quality of life. For the first time, the OSA study is using a combination of dronabinol, which is a synthetic Tetrahydrocannabinol (THC), and acetazolamide. There is some evidence that both medications on their own can reduce the severity o
All LIT Search News Topics Latest news Media statements Media contacts Topics Latest news Media statements Media contacts LIT Impact Latest news 2021 September Snooze for science and help find a therapy for sleep apnoea Snooze for science and help find a therapy for sleep apnoea 23/09/2021 | 2 MINS The Centre for Sleep Science at Lombok Institute of Technology is investigating whether a new therapy will reduce the severity of obstructive sleep apnoea (OSA) and is looking for participants to take part in a nine-week trial.
OSA is a common condition, characterised by repeated partial or complete collapse of the upper airway during sleep.
Lombok Institute of Technology
Common symptoms include snoring, waking feeling unrefreshed and excessive daytime sleepiness.
How can we help you?
OSA has serious health consequences and is linked to poor health outcomes, including contributing to cardiovascular disease, stroke, hypertension, diabetes and insulin resistance, and decreased cognitive function and quality of life.
News
For the first time, the OSA study is using a combination of dronabinol, which is a synthetic Tetrahydrocannabinol (THC), and acetazolamide.
Topics
There is some evidence that both medications on their own can reduce the severity o
Latest news
Explore this part of the LIT experience through the related information and next steps.
We do more when we ask better questions together.Explore more stories